Identification and development of vascular disrupting agents: Natural products that interfere with tumor growth

Natural Products and Cancer Drug Discovery

Volumn , Issue , 2013, Pages 17-38

  Hooper, Andrea T ^a   Loganzo, Frank ^a   May, Chad ^a   Gerber, Hans Peter ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922322720     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4654-5_2     Document Type: Chapter

References (109)

1. Asahina A, Tada Y et al (2001) Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells-evidence for the association of VCAM-1 expression with microtubules. J Dermatol Sci 25(1):1-9.
2. Atalay C, Deliloglu Gurhan I et al (2006) Multidrug resistance in locally advanced breast cancer. Tumour Biol 27(6):309-318.
3. Baguley BC, Siemann DW (2010) Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs 19(11):1413-1425.
4. Baguley BC, Holdaway KM et al (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27(4):482-487.
5. Bai RL, Pettit GR et al (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265(28):17141-17149.
6. Banerjee S, Wang Z et al (2008) Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71(3):492-496.
7. Bellmunt J, Theodore C et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454-4461.
8. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603.
9. Bibby MC, Double JA (1993) Flavone acetic acid-from laboratory to clinic and back. Anticancer Drugs 4(1):3-17.
10. Bibby MC, Double JA et al (1987) Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 55(2):159-163.
11. Bibby MC, Double JA et al (1989) Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 81(3):216-220.
12. Brooks AC, Kanthou C et al (2003) The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res 23(4):3199-3206.
13. Carmeliet P, Jain RK (2011a) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307.
14. Carmeliet P, Jain RK (2011b) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427.
15. Chabot GG, Branellec D et al (1993) Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse. Eur J Cancer 29A(5):729-733.
16. Chan LS, Malcontenti-Wilson C et al (2007) Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res 27(4B): 2317-2323.
17. Chaplin DJ, Pettit GR et al (1999) Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19(1A):189-195.
18. Ching LM, Goldsmith D et al (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59(14):3304-3307.
19. Ching LM, Cao Z et al (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86(12):1937-1942.
20. Ching LM, Zwain S et al (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90(4):906-910.
21. Chung F, Liu J et al (2008) Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemother Pharmacol 61(3):497-502.
22. Clauss M, Sunderkotter C et al (2001) A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97(5):1321-1329.
23. Cronstein BN, Molad Y et al (1995) Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 96(2):994-1002.
24. Culine S, Theodore C et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94(10):1395-1401.
25. D'Amato RJ, Lin CM et al (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 91(9):3964-3968.
26. Dark GG, Hill SA et al (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57(10):1829-1834.
27. Darland DC, D'Amore PA (1999) Blood vessel maturation: vascular development comes of age. J Clin Invest 103(2):157-158.
28. Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45(1):136-139.
29. Denekamp J, Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46(5):711-720.
30. Double JA, Bibby MC et al (1986) Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon. Br J Cancer 54(4):595-600.
31. Ferrara N, Mass RD et al (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491-504.
32. Finkelstein Y, Aks SE et al (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 48(5):407-414.
33. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203.
34. Galbraith SM, Chaplin DJ et al (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21(1A):93-102.
35. Greystoke A, Blagden S et al (2006) A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 17(8):1313-1319.
36. Grosios K, Holwell SE et al (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81(8):1318-1327.
37. Harris SR, Thorgeirsson UP (1997) Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. Biochem Biophys Res Commun 235(3):509-514.
38. Havlin KA, Kuhn JG et al (1991) Phase I clinical and pharmacokinetic trial of flavone acetic acid. J Natl Cancer Inst 83(2):124-128.
39. Hill BT, Fiebig HH et al (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35(3):512-520.
40. Holwell SE, Hill BT et al (2001) Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84(2):290-295.
41. Honore S, Pagano A et al (2008) Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 7(7):2080-2089.
42. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66(24):11520-11539.
43. Horsman MR, Murata R et al (2000) Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476:311-323.
44. Horti J, Juhasz E et al (2008) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol 62(1):173-180.
45. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9(6):685-693.
46. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
47. Jain RK, Duda DG et al (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3(1):24-40.
48. Joseph WR, Cao Z et al (1999) Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59(3):633-638.
49. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99(6):2060-2069.
50. Kim TJ, Ravoori M et al (2007) Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67(19):9337-9345.
51. Kobayashi M, Natsume T et al (1997) Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88(3):316-327.
52. Kruczynski A, Hill BT (2001) Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40(2):159-173.
53. Kruczynski A, Barret JM et al (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55(5):635-648.
54. Kruczynski A, Poli M et al (2006) Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42(16):2821-2832.
55. Lankester KJ, Maxwell RJ et al (2007) Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 30(2):453-460.
56. Lara PN Jr, Douillard JY et al (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29(22):2965-2971.
57. Lash CJ, Li AE et al (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78(4):439-445.
58. Li L, Rojiani A et al (1998) Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42(4):899-903.
59. Lin CM, Singh SB et al (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34(2):200-208.
60. LoRusso PM, Gadgeel SM et al (2008) Phase I clinical evaluation of ZD6126, a novel vasculartargeting agent, in patients with solid tumors. Invest New Drugs 26(2):159-167.
61. Ludford RJ (1948) Factors determining the action of colchicine on tumour growth. Br J Cancer 2(1):75-86.
62. Mabjeesh NJ, Escuin D et al (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363-375.
63. Madlambayan GJ, Meacham AM et al (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 116(9):1539-1547.
64. McKeage MJ, Von Pawel J et al (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99(12):2006-2012.
65. McKeage MJ, Reck M et al (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65(2):192-197.
66. Micheletti G, Poli M et al (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63(7):1534-1537.
67. Mikaelian I, Buness A et al (2010) Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol Sci 117(1):144-151.
68. Natsume T, Watanabe J et al (2000) Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 91(7):737-747.
69. Natsume T, Watanabe J et al (2003) Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 94(9):826-833.
70. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6):436-446.
71. Ngan VK, Bellman K et al (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60(18):5045-5051.
72. Otani M, Natsume T et al (2000) TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91(8):837-844.
73. Parkins CS, Holder AL et al (2000) Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83(6):811-816.
74. Patel S, Keohan ML et al (2006) Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 107(12):2881-2887.
75. Pettit GR, Cragg GM et al (1987) Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 50(3):386-391.
76. Pettit GR, Singh SB et al (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45(2):209-211.
77. Pili R, Rosenthal MA et al (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16(10): 2906-2914.
78. Plowman J, Narayanan VL et al (1986) Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70(5):631-635.
79. Pluda JM (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24(2):203-218.
80. Pourroy B, Honore S et al (2006) Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66(6):3256-3263.
81. Pratt CB, Relling MV et al (1991) Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am J Clin Oncol 14(6):483-486.
82. Prise VE, Honess DJ et al (2002) The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21(4):717-726.
83. Rewcastle GW, Atwell GJ et al (1989) Potential antitumor agents. 58. Synthesis and structureactivity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem 32(4):793-799.
84. Riely GJ, Gadgeel S et al (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55(2):181-185.
85. Schoffski P, Thate B et al (2004) Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15(4):671-679.
86. Shimoyama T, Hamano T et al (2006) Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro. Pharmacogenomics J 6(6):388-396.
87. Siegenthaler P, Kaye SB et al (1992) Phase II trial with flavone acetic acid (NSC.347512, LM975) in patients with non-small cell lung cancer. Ann Oncol 3(2):169-170.
88. Siemann DW, Mercer E et al (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99(1):1-6.
89. Siim BG, Lee AE et al (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51(1):43-52.
90. Stafford SJ, Schwimer J et al (2005) Colchicine and 2-methoxyestradiol inhibit human angiogenesis. J Surg Res 125(1):104-108.
91. Subbiah IM, Lenihan DJ et al (2011) Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8):1120-1130.
92. Tamura K, Nakagawa K et al (2007) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 60(2):285-293.
93. Thomsen LL, Ching LM et al (1990) Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 50(21):6966-6970.
94. Thomsen LL, Ching LM et al (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51(1):77-81.
95. Thomsen LL, Ching LM et al (1992) Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues. Biochem Pharmacol 43(11):2401-2406.
96. Tozer GM, Prise VE et al (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61(17):6413-6422.
97. Tozer GM, Kanthou C et al (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5(6):423-435.
98. Venditti JM, Wesley RA et al (1984) Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 20:1-20.
99. Verenich S, Gerk PM (2010) Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm 7(6):2030-2039.
100. Vincent L, Kermani P et al (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115(11):2992-3006.
101. Wahl O, Oswald M et al (2011) Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 18(21):3136-3155.
102. Watanabe J, Natsume T et al (2006) Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. Cancer Sci 97(12):1410-1416.
103. Watanabe J, Endo Y et al (2007) Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells. In Vivo 21(2):297-304.
104. Young SL, Chaplin DJ (2004) Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 13(9):1171-1182.
105. Yun-San Yip A, Yuen-Yuen Ong E et al (2008) Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 17(4):583-591.
106. Zhao L, Ching LM et al (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87(4):465-470.
107. Zhao L, Ching LM et al (2005) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 116(2):322-326.
108. Zwi LJ, Baguley BC et al (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 81(13):1005-1013.
109. Zwi LJ, Baguley BC et al (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6(2):79-85.